Special Delivery TRIZ Cases
- Muscle-Targeting Antibody Complexes for Dystrophin Payload Delivery
Muscle-targeting antibodies use receptor-mediated internalization to deliver oligonucleotides and support dystrophin exon skipping in muscle cells.
- Aptamer Delivery Mechanisms for Pre-Exposure Pollutant Protection
DNA- or RNA-delivered aptamers bind toxic metals before absorption, helping reduce reliance on chelation therapy after cumulative exposure.
- PCSK9 Gene Editing via Guide RNA and Lipid Nanoparticles
Excess PCSK9 can elevate LDL cholesterol; guide RNA and Cas9 delivered in lipid nanoparticles target the gene to reduce its expression.
- MUC5B-Targeted dsRNA Silencing for Distal Lung Fibrosis
Targeted dsRNA silences excess MUC5B associated with rs35705950-T, addressing fibrosis progression while preserving upper-airway infection protection.
- Formula 1A Cationic Lipid Synthesis for Intracellular Delivery
Sequential esterification, substitution, hydrogenation, protection, and hydrolysis produce a lipid for targeted nucleic acid delivery.
- Exosome-Loaded HBB Therapy for Nonviral Sickle Cell Treatment
Exosome carriers deliver HBB DNA and rs334-targeting siRNA to address sickle cell mutations without viral-vector integration or chemotherapy.
- L1 Retrotransposon RNA Modulation for Bone Mass and Aging
Nucleic acids, expression vectors, and antisense oligonucleotides adjust L1 RNA activity to support bone mass or reduce aging-linked cellular activity.
- Spherical Nucleic Acid Constructs for Localized TLR Activation
Controlled surface density of TLR 7/8 and 9 agonists concentrates immune stimulation on nanoscale constructs, improving response while reducing systemic toxicity.
- Hammerhead Ribozyme Stem II Modifications for Faster RNA Cleavage
Stem II loop sequences and a position-7 uracil improve hammerhead ribozyme turnover for more efficient target RNA cleavage.
- Variant-Selective C1858T PTPN22 siRNA for Autoimmune Therapy
Sequence-specific siRNA silences the C1858T PTPN22 allele while sparing wild-type function and reducing IL-2 production in T lymphocytes.